John Mendelsohn joins Merrimack board
This article was originally published in Scrip
Executive Summary
Merrimack Pharmaceuticals, a biopharmaceutical company developing innovative medicines paired with companion diagnostics to treat cancer, has appointed Dr John Mendelsohn to its board of directors. Dr Mendelsohn served as president of the University of Texas MD Anderson Cancer Center from 1996-2011 and remains on the faculty as co-director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy.